Roles of circadian clocks in cancer pathogenesis and treatment

Yool Lee 1

© The Author(s) 2021

INTRODUCTION
Circadian clocks are ubiquitous timing mechanisms that generate approximately 24-h rhythms in cellular and bodily functions across nearly all living species. These internal clock systems enable living organisms to anticipate and respond to daily changes in their environment in a timely manner, optimizing temporal physiology and behaviors. Dysregulation of circadian rhythms by genetic and environmental risk factors increases susceptibility to multiple diseases, particularly cancers. A growing number of studies have revealed dynamic crosstalk between circadian clocks and cancer pathways, providing mechanistic insights into the therapeutic utility of circadian rhythms in cancer treatment. This review will discuss the roles of circadian rhythms in cancer pathogenesis, highlighting the recent advances in chronotherapeutic approaches for improved cancer treatment.

Mechanism of circadian physiology
The basic architecture of circadian rhythm mechanisms across living species on earth is typically characterized by a cell-autonomous autoregulatory feedback loop. In eukaryotes, a subset of dedicated positive and negative clock regulators forms the interlocked transcriptional translational feedback loop to constitute a cell-autonomous oscillator that drives the rhythmic expression of output genes involved in metabolic, biosynthetic, signal transduction, and cell cycle pathways. In mammals, the BMAL1 and CLOCK transcriptional activator complex cyclically drive the transcription of its own repressors, period (PER), and cryptochrome (CRY). The core oscillator is complemented by a second loop in which periodic expression of BMAL1 is maintained by the REV-ERBα/β repressor and retinoic acid receptor-related orphan receptor (ROR) α/β activator proteins. In addition to the core regulatory loops, multiple levels of epigenetic, posttranscriptional, and posttranslational regulation that involve various kinases and phosphatases, ubiquitin–proteasome pathway components, nuclear–cytoplasmic transporters, noncoding RNAs, and chromatin remodelers contribute to the molecular clockwork, thus coordinating temporal programs via multiple clock-output genes.

This molecular clockwork is shared across the brain and peripheral organ systems, constituting a body-wide circadian network. In the brain, intracellular oscillators in approximately 20,000 individual neurons and astrocytes comprise the hypothalamic suprachiasmatic nucleus (SCN), a central circadian pacemaker. The principal role of the SCN clock is to communicate retinal light information received from the retinohypothalamic tract (RHT) to peripheral clock systems, thus mediating the periodic synchronization of internal body rhythms with external day and night cycles. In a hierarchical organization model, the SCN master clock orchestrates circadian phases in non-SCN subordinate brain clocks via rhythmic release of neurotransmitters and neuropeptides, as well as in peripheral organ clocks via systemic hormonal secretion and neural innervations, thereby coordinating rhythmic output physiology and behaviors with daily environmental changes.

For example, the SCN coordinates the rhythmic, antiphase secretion of the night sleep hormone melatonin from the pineal gland with the release of the morning stress hormone GC from the adrenal glands via the sympathetic nervous system to ensure daily rhythms in sleep/wake, as well as neural, metabolic, and immune functions. In addition, the brain master clock controls other
peripheral clock functions in the heart, kidney, pancreas, lung, intestine, and thyroid glands through circadian modulation of the autonomic nervous system\textsuperscript{14}.

In addition to SCN-dependent clock entrainment, non-SCN brain regions and peripheral tissues possess their own autonomous and multistimuli entrainable oscillators that influence not only circadian functions in the SCN and neighboring local clocks but also behavioral rhythms via neural, hormonal, and metabolic feedback mechanisms\textsuperscript{15,16}. Moreover, multiple nonphotic physiological (e.g., redox cofactors, reactive oxygen species, microbial products) and environmental (e.g., temperature, food intake, exercise, and pathogenic infections) cues control extra-SCN brain and peripheral clock functions, which, in turn, impact the entire host clock system via neural and immunometabolic circuits\textsuperscript{17–19}.

These findings suggest that real-world circadian rhythms are achieved through multimode regulation of tightly coupled body clocks under daily changes in internal and external processes.

**Circadian disruption and cancer pathogenesis**

The growing knowledge of chronobiological mechanisms has increased our understanding of how rhythm disturbances by multiple physiological and environmental factors impact pathogenesis in diseases such as cancer (Fig. 3). Disrupted circadian rhythmicity has been a prominent feature of modern society since the invention of artificial light sources. Indeed, 80% of the world's population is now exposed to light during the night, and approximately 18–20% of workers in the USA and Europe are involved in night or rotating shift work, making them vulnerable to multiple rhythm disorders, including cancer\textsuperscript{20}.

Several epidemiological studies further suggest that night shift work or chronic jet lag increases the risk of the incidence and development of the most common cancer types (i.e., breast, lung, prostate, colorectal, and skin cancers)\textsuperscript{2}. Based on this evidence, the International Agency for Research on Cancer (IARC) classified “shift-work that involves circadian disruption” as potentially “carcinogenic to humans (Group 2A)” in 2007 and again in 2019\textsuperscript{21}.

The results from several studies of animal models exposed to forced circadian desynchrony regimens have also reinforced the causal relationship between circadian disturbances and cancer pathogenesis. In an earlier mouse model study, SCN ablation or exposure to experimental chronic jetlag (CJL, consisting of an 8-h advance of the light-dark cycle every 2 days) was shown to cause alterations in circadian physiology and significantly accelerate the growth rates of transplanted tumors (Glasgow osteosarcoma and pancreatic adenocarcinoma)\textsuperscript{22}. Subsequent animal studies showed that circadian rhythm disruptions induced by CJL promoted lung tumor growth and progression with altered immune functions\textsuperscript{4,23}. Furthermore, CJL conditions have been observed to accelerate tumor cell cycle progression and growth rates in carcinogen-induced tumors as well as grafted melanomas in mice\textsuperscript{9}. In line with these results, another murine melanoma model study reported that circadian disruption facilitates tumor-immune microenvironment remodeling that favors tumor cell proliferation\textsuperscript{6}. More recently, chronic circadian disruption has also been shown to promote breast cancer cell dissemination and metastasis in mice by increasing the stemness and tumor-initiating potential of tumor cells and by creating an immuno-suppressive shift in the tumor microenvironment\textsuperscript{5}.

![Fig. 1  Circadian molecular clock mechanism. This autoregulatory feedback loop cycles between the CLOCK/BMAL1 transcriptional activator complex and its repressors (PER/CRY, REV-ERBa) or activators (RORa/b) to constitute the molecular clock oscillator that drives the expression of multiple clock-controlled genes (CCGs), such as metabolic genes, signaling genes, and epigenetic regulators.](image-url)
Roles of circadian clock components in cancer

At the molecular and cellular levels, there is close crosstalk between the circadian clock machinery and the cell cycle, DNA repair, apoptosis, senescence, autophagy, and other oncogenic and immune pathways. Circadian perturbations dysregulate these processes, leading to uncontrolled proliferation, escape from apoptosis, metastatic spread, immune evasion, enhanced angiogenesis, and anticancer drug resistance, which are all hallmarks of cancer. In this regard, multiple loss- and gain-of-function studies with cellular and animal models have demonstrated the direct involvement of clock genes in cancer predisposition and development. Epigenetic or genetic inactivation of *Bmal1* and/or *Clock* has been shown to increase tumor proliferation or growth rates in several types of cancer, such as hematologic cancer, colon cancer, pancreatic cancer, tongue squamous cell carcinoma (TSCC), breast cancer, lung adenocarcinoma, hepatocellular carcinoma (HCC), nasopharyngeal carcinoma (NPC), and glioblastoma (GBM). Conversely, overexpression of these circadian activators suppresses proliferative and malignant phenotypes in tumor cells via mechanisms involving cell cycle arrest and p53-dependent apoptosis. Similarly, downregulation or upregulation of *Per1*, *Per2*, and *Cry1*, the principal target genes of BMAL1/CLOCK, has been shown to promote or suppress tumor incidence and proliferation, respectively, in multiple cancer cell types, including Lewis lung carcinoma and mammary carcinoma cells, pancreatic cancer, lung carcinoma, leukemia, glioma, ovarian cancer, and oral squamous cell carcinoma. The potential anticancer mechanism exerted by PER1/2 has been suggested to involve the inhibition of PI3K/AKT/mTOR-mediated glycolysis as well as cell cycle arrest and apoptosis induction. As an additional tumor-controlling mechanism, the Lamia group has reported that CRY1 and/or CRY2 promote the degradation of cMYC, early factors (E2F) family members, and tousled-like kinase 2 (TLK2) by recruiting these cell cycle-related oncogenic factors to the SCFFBXL3 ubiquitin-ligase complex. Consistent with these results, a recent large-scale systems analysis of 32 human cancer types revealed that PERs and CRYs, among several other clock genes, are downregulated in multiple cancers. Overall, these findings highlight the tumor suppressor functions of canonical clock components in most cancer types.

On the other hand, some studies show that the core clock genes exert tumor promotive functions, depending on the cancer cell status or type. For example, BMAL1 silencing was observed to lead to a substantial increase in apoptosis with mitotic and morphological abnormalities in malignant pleural mesothelioma (MPM) cells. Similarly, knockdown of either *Bmal1* or *Clock* has been observed to induce cell cycle arrest and apoptosis in cancer
recently, CRY1 has been suggested to be a critical factor for local invasion and distant metastasis of tumors. More expression of matrix metalloproteinase 9 (MMP9), a mediating factor in these processes, has been observed in tumors with compromised or disordered rhythms, thus improving the response to anticancer treatment. 

For example, training the clock can be implemented to strengthen the compromised or disordered rhythms, thus improving the effects of clocked drugs or drugging the clock. With these strategies in mind, in the following sections, we describe recent approaches to improve cancer prevention and treatment via the improvement or correction of circadian rhythms depending on the type and state of the cell (Fig. 4).

Targeting circadian rhythms in cancer treatment

Further insights into circadian rhythms and their related diseases have ignited growing interest in how these processes can be utilized to improve cancer prevention and treatment. In a recent review article, Sulli et al. nicely categorized chronotherapeutic approaches into three types: (1) training the clock: interventions to enhance or maintain a robust circadian rhythm in feeding-fasting, sleep-wake, or light-dark cycles; (2) drugging the clock: using small-molecule agents that directly target a circadian clock; and (3) clocking the drugs: optimizing the timing of drugs to improve efficacy and reduce adverse side effects (Fig. 3). These chronobiological concepts are not exclusive to each other but have been applied to cancer treatment in a combinatorial manner. For example, training the clock can be implemented to strengthen the compromised or disordered rhythms, thus improving the effects of clocked drugs or drugging the clock. With these strategies in mind, in the following sections, we describe recent chronobiological approaches in cancer therapy.

Training circadian clocks for cancer treatment. Based on the rhythm entrainment mechanism by photic stimuli, morning bright light (MBL) exposure has been widely implemented to cure sleep disorders (e.g., advanced or delayed sleep phase syndromes), neuropsychiatric diseases (e.g., autism spectrum disorder, attention deficit hyperactivity disorder, and dementia), and metabolic disorders (e.g., diabetes and obesity) in preclinical or clinical settings. In line with this, light therapy has been an emerging chronotherapeutic tool to mitigate cancer progression. Accumulated studies with a human cancer xenograft model have revealed that daytime blue light enhances nighttime circadian melatonin inhibition of tumor growth in prostate, liver, and breast cancers. These results correspond with previous reports showing that melatonin depletion by light exposure late at night stimulates the growth of multiple human cancer xenografts and increases anticancer drug resistance. Other experimental human studies with a simulated night shift work model have shown that bright light induces complete and rapid adjustment of peripheral clocks, suggesting that phototherapy may be a potential nonpharmacological intervention to counteract the progressive effects of shift work or jet lag on tumors. Overall, these studies suggest that targeting the brain–neurohormone axis holds promise for achieving multiple therapeutic benefits in cancer prevention and treatment via the improvement or correction of circadian rhythms.

In recent studies, nutritional interventions have been increasingly thought to improve circadian rhythms and health. Indeed, mouse studies have revealed that circadian molecular and metabolic profiles altered by aging are reverted by caloric restriction (CR), a well-known antiaging dietary intervention. In addition to its antiaging effects, increasing preclinical evidence indicates that CR may have anticancer effects by reducing tumor progression, enhancing the death of cancer cells, and elevating the effectiveness and tolerability of chemo- and radiotherapies. Nonetheless, it is increasingly recognized that chronic CR often has detrimental effects on tumor development and chemotherapy in cancer patients, possibly by negatively affecting the immune system, wound healing, and other important functions. As an alternative, intermittent fasting (IF), a diet-based therapy that...

![Fig. 3 Chronodisruptive factors and chronotherapeutic interventions in cancer pathogenesis and treatment.](Image 104x506 to 500x732)
alternates between fasting and free feeding/eating for a period of time, has been reported to inhibit tumor growth and improve antitumor immune responses in preclinical and clinical studies. Furthermore, IF can increase cancer sensitivity to chemotherapy and radiotherapy and reduce the side effects of traditional anticancer treatments. Taken together, this body of evidence suggests that well-designed chronodietary intervention holds promise as a potential therapeutic regimen to counter cancer, with fewer side effects and more safety.

Along with diet, exercise is gaining emerging attention as a potential chronotherapeutic intervention strategy for the prevention and treatment of multiple disease processes. Notably, increasing numbers of human studies have revealed the therapeutic benefits of exercise in cancer treatment and survival. Compared to mice treated with chemotherapy alone, mice treated with exercise plus chemotherapy presented with delayed tumor growth models in breast cancer, melanoma, and pancreatic cancer. However, most of these studies were performed without considering the effects of exercise timing on these disease processes. In this regard, a recent, population-based, case-control study reports that those who exercise in the early morning may have reduced risks of developing prostate or breast cancer than those who exercise in the evening. In the future, it would be interesting to investigate how the timing of exercise influences cancer progression and chemotherapeutic outcomes with more mechanistic approaches.

In parallel with nonpharmacological interventions, several experimental and clinical studies have suggested that melatonin is an effective anticancer hormone beyond its circadian entrainment function. A meta-analysis of randomized controlled trials revealed that low secretion of melatonin is associated with a higher incidence of cancer development in patients with exposure to light during nighttime hours. Moreover, melatonin has the capacity to act specifically on cancer cells, not on normal cells. Melatonin also reduces chemotherapy-induced toxicity on normal cells through the re-establishment of the light/dark circadian rhythm. These results hold promise for establishing melatonin therapy as one of the safest chronobiotic strategies in the treatment of cancer.

Similar to melatonin, glucocorticoids (GCs) are also anticancer hormones. GCs are steroid hormones that are rhythmically secreted from the adrenal gland via SCN modulation of the hypothalamic–pituitary–adrenal stress response axis. GC levels peak in the morning as a strong circadian cue to reset the peripheral tissue clock, and they have a systemic influence on metabolic (e.g., gluconeogenesis) and immune (e.g., anti-inflammatory) functions. The synthetic GC steroid dexamethasone (Dex) has been used as a supportive care comedication for cancer patients undergoing standard care pemetrexed/platinum doublet chemotherapy. In particular, GCs have been very effective in the treatment of lymphoid malignancies, including leukemia, lymphomas, and MM, with much work being done to enhance their effects and overcome resistance. Interestingly, a recent animal study showed that enhancing the circadian clock with Dex treatment reduced tumor proliferation and growth in mouse melanoma. Despite their tumor suppressor function, recent clinical reports suggest that GCs may also be implicated in poorer responses to cancer therapies with immune checkpoint inhibitors, such as anti-PD-(L)1, due to their immunosuppressive functions. Given the diurnal fluctuation in endogenous GC levels, it would therefore be important to consider the dose and administration timing of corticosteroids to improve efficacy and safety in their use with immune-based cancer therapies.

Fig. 4 Divergent roles of circadian clock components in cancer. Enhanced levels or activity of circadian clock components (e.g., CLOCK/ BMAL1) inhibit tumor proliferation and growth by promoting the degradation of oncoproteins (e.g., cMYC, E2F, and TLK2), cell cycle arrest, apoptotic cell death, metabolic defects, and cytotoxic immunity in multiple cancers, as indicated. On the other hand, the core clock components may also exert tumor-suppressive functions in some cancer cell types (e.g., mesothelioma, leukemia stem cells, glioblastoma stem cells) by inhibiting tumor progression upon downregulation. E2F early 2 factor, TLK2 tousled like kinase 2.
range of neuropsychiatric, metabolic, and immune disorders, as well as cancers. Synthetic REV-ERB agonists, such as SR9009 and SR9011, induce wakefulness, suppress sleep, regulate emotional behavior, and reduce anxiety-like behavior in mice. Notably, recent in vitro and in vivo studies have revealed that REV-ERB agonists (SR9009 and SR9011) exhibit selective anticancer properties in brain, leukemia, breast, colon, and melanoma cancer cell lines by inhibiting autophagy and de novo lipogenesis important for cancer cell survival. The antitumor effect of the REV-ERB agonist SR9009 was further confirmed by subsequent studies showing that treatment with this drug significantly reduced cell proliferation and viability in glioma cells as well as chemoresistant and chemosensitive small-cell lung carcinoma cells by impairing autophagy. Additional potential targets for treating cancer include several ROR isoforms and positive transcriptional regulators of Bmal1 expression. Notably, emerging studies report that pharmacological inhibition of RORγ in vitro and in vivo exerts potent antitumor activity in multiple cancer types, such as castration-resistant prostate cancer, pancreatic adenocarcinoma, and triple-negative breast cancer. On the other hand, synthetic RORγ agonists have also been reported to enhance antitumor immunity by increasing cytotoxic lymphocyte functions and attenuating immunosuppressive mechanisms. Indeed, the ROR agonist LYC-55716 has been actively implemented in preclinical and clinical trials, showing good tolerability, safety, and pharmacokinetics in single or combined treatment with existing immunotherapeutic agents. Notably, nobiletin, a dietary flavonoid found in citrus fruits, has been recently characterized as an agonist of RORα and RORγ that can induce apoptosis and cell cycle arrest, suppress migration and invasion, inhibit many oncogenic drivers, upregulate tumor suppressors, and increase chemotherapy sensitivity across several cancer cell types. These results suggest that ROR isoforms may be a promising target for the treatment of cancers.

Increasing numbers of reports have suggested a potential role for CRY modulators in metabolic disease and cancer treatments. Hirota and colleagues first reported that KL001, a CRY stabilizer identified via cell-based high-throughput circadian assays, was found to lengthen the circadian period in a variety of cells and tissues and block glucagon-dependent induction of gluconeogenesis in cultured hepatocytes. Remarkably, in a recent study, KL001 exhibited antitumor activity, such as impaired self-renewal, cell migration, and proliferation, as well as increased apoptosis, in patient-derived GBM stem cells. However, another study showed that KL001 promoted cancer cell migration but had no effects on cell proliferation or colony formation in U2OS human osteosarcoma cells. Interestingly, the CRY1/2 inhibitor KS15 has been reported to reduce MCF-7 cell growth and increase chemosensitivity in human breast cancer cells, possibly via the drug-induced elevation of PER2, a tumor suppressor clock protein. These findings suggest that the antitumor effects of CRY modulators in cancer cells involve divergent mechanisms that are cell type-specific.
Clocking medicine for cancer treatment. It has been well documented that circadian clocks regulate the absorption, distribution, metabolism, and elimination of drugs. Furthermore, growing experimental and clinical evidence suggests that the circadian timing of medicine can be an important parameter in disease treatment, including chemotherapy. Numerous clinical studies have shown that the efficacies of over 30 chemotherapeutic drugs can vary by over 50% depending on when they are administered. Due to the cytotoxic effects of anticancer drugs on normal tissues as well as malignant cells, a major goal of chrononcancer therapeutic studies is to reduce the toxicity that results in host tissue damage and immunological dysfunction (Fig. 5a). Early human studies in patients with advanced ovarian cancer showed that administration of doxorubicin in the morning (e.g., at 6 am) and cisplatin in the evening (e.g., at 6 pm before or after doxorubicin) caused fewer complications and less renal toxicity, along with dose reductions and treatment delays, when compared with administration of doxorubicin in the evening and cisplatin in the morning. Likewise, in several clinical trials with patients with metastatic colorectal cancer, chronotherapy with irinotecan, oxaliplatin, 5-fluorouracil (5-FU), and leucovorin in combination resulted in advantages in time to progression and overall survival, with increased tolerability and safety compared to routine chemotherapy.

Importantly, extensive studies have unraveled potential mechanisms underlying chronomodulated chemodrug safety. Computational analysis with experimental and clinical results has revealed that the same temporal pattern of drug (e.g., 5-FU and oxaliplatin) administration can result in minimal cytotoxicity in one cell population (e.g., normal cells), while at the same time, it can display high cytotoxicity in another cell population (e.g., tumor cells). These analyses underscore a potential advantage of chronotherapy in improving the simultaneous chronotolerance and chronoefficacy of anticancer drugs. For example, at the molecular level, the rhythmic response and toxicity of 5-FU are dependent upon circadian oscillations in thymidylate synthase activity, its molecular target, and dihydropyrimidine dehydrogenase activity (DPD), the rate-limiting enzyme responsible for its elimination. In line with this, a recent clinical study has shown that circadian oscillation of the DPD enzyme, with the peak of activity occurring at 4 pm and the trough of activity occurring at 4 am, modulates the time-dependent bioavailability and efficacy of 5-FU. Moreover, the levels of glutathione (GSH), an antioxidant tripeptide involved in drug detoxification, were also found to fluctuate daily, with peak concentrations occurring in the afternoon (~4 pm); therefore, platinum drug (e.g., cisplatin and oxaliplatin) toxicities were reduced when they were administered within the peak GSH time window. Indeed, current knowledge of these circadian mechanisms has been widely leveraged to design and implement recent clinical trials, such as the induction of chronomodulated chemotherapy with 5-FU or cisplatin plus radiotherapy for NPC, with growing results showing reductions in adverse effects and enhanced tolerance with thoughtful, timed treatment approaches.

In addition to host circadian rhythms, it has been suggested that daily cell-cycle dynamics in tumors can also be targeted for the time-of-day efficacy of anticancer therapy (Fig. 5b). In particular, cell cycle rhythm has been considered one of the most determinant factors in chronocancer therapy since 24-h mitotic rhythmicity was reported in human mammary cancer cell biopsy samples. Notably, a flow cytometry study of cells from ovarian cancer patients revealed that tumor cell proliferation, as determined by the percentage of cells in the S (DNA synthesis) phase, exhibits a highly significant 24-hour rhythm, with a peak in the mid-to-late morning that is nearly 12 h out of phase with non-tumor cell proliferation in normal tissues. (Fig. 5a, b). Along these lines, preclinical and clinical cancer studies reporting on the chronotimeliness of cell cycle phase-specific drugs, such as cisplatin or 5-fluorouracil (5-FU) (S phase-specific), docetaxel (M phase-specific), and seliciclib (G1 phase-specific), showed that their maximal efficacy and minimal toxicity were achieved at different times during the day. Furthermore, palbociclib (PD-0332991), a selective inhibitor of cyclin-dependent kinase (CDK) 4/6, which is responsible for G1/S cell cycle progression, was found to reduce the growth of cultured cells and mouse tumors in a time-of-day-specific manner. Together, these findings argue for chemotherapeutic approaches that are timed to coincide with times of high tumor cell vulnerability and low toxicity to normal tissues (Fig. 5).

Increasing evidence suggests direct roles for circadian clock gene mechanisms in modulating the efficacy of anticancer therapies depending on the time of day. In recent individual chronopharmacological studies, the DNA alkylator temozolomide and irinotecan, a topoisomerase I inhibitor, was shown to exhibit rhythmic drug toxicity in GBM and colorectal cancer cells, respectively, with maximum drug sensitivity occurring near the peak of BMAL1 expression. These cytotoxic rhythms were ablated when BMAL1 was silenced. These studies coincide with other reports indicating that elevated BMAL1 expression increases the sensitivity of colorectal cancer and TSCC cells to oxaliplatin and paclitaxel. Similar to BMAL1, a recent mouse tumor graft study with human oral squamous cell carcinoma (OSCC) cells suggested that PER2 is an effective chronomodulator of DNA damaging agents (e.g., oxaliplatin) since the efficacies of these drugs can be greatly boosted with timely administration at the peak of PER2 expression. In further molecular analyses, PER2 was shown to periodically suppress proliferating cell nuclear antigen transcription, which, in turn, impeded the drug-induced DNA repair mechanism, thus increasing chronodrug sensitivity.

In addition, other individual studies using in vitro or in vivo tumor graft models showed that synthetic (e.g., SR9009, bortezomib, and aldehyde dehydrogenase inhibitor) and natural (e.g., curcumin) compounds could exert time-of-day-dependent anti-tumor activity via multiple circadian-dependent metabolic factors in GBM, liver, and breast cancer cells. In line with these findings, a recent large-scale chronopharmacological analysis revealed that multiple anticancer drugs, including HSP90 inhibitors, exhibit time-of-day cytotoxicity, which requires cell cycle rhythms; however, these effects were abrogated in clock-deficient cancer cells. In further analyses, Bmal1 ablation was shown to critically affect melanoma proliferation and time-of-day sensitivity to an HSP90 inhibitor in vivo. Overall, these results clearly suggest that circadian regulation of cellular dynamics in tumors can dictate the time-of-day specificity of anticancer drugs (Fig. 5c).

Notably, it is increasingly recognized that chronotype, sex, age, disease status, and other interpersonal differences in rhythm status can largely affect pharmacodynamic variability among cancer patients, posing a daunting challenge in cancer drug therapy. In particular, growing numbers of experimental and clinical studies suggest that environmental or physiological perturbations of circadian rhythms, such as shift work, abnormal sleep timing, irregular psychosociological stresses, and critical illness, can underlie interindividual variability in both cancer growth and response to cancer therapy. Circadian disruption may also be related to the chronic sleep loss and depression suffered by many cancer patients following diagnosis and treatment. Thus, it can be anticipated that training or enhancing the body clock with scheduled light exposure, mealtimes, or exercise, alongside a carefully timed chemotherapy regimen, would improve antitumor treatment.

**CONCLUDING REMARKS**

In recent decades, extensive chronobiological research has expanded our understanding of the functional roles and mechanisms of the circadian clockwork in human health and
diseases, including cancer. Circadian disruptions negatively influence both tumor molecular clocks and host circadian systems to increase cancer risk and progression. On the other hand, given the close link between cancers and other rhythm-disruptive pathologies, such as aging, obesity, and diabetes, enhancing circadian rhythms with chronophysiologic interventions (e.g., chronophototherapy, chronodiet, and chronoeexercise) is expected to highly benefit overall circadian health and cancer therapy. In addition, the dose timing of chemotherapeutic agents is an important therapeutic option that can improve tumor-specific cytotoxicity while sparing normal cells and host tissues. With the growing development of chronotherapeutic tools and strategies, it may be reasonable to expect that integrative chronotherapy will further improve the prevention and treatment of cancer.

REFERENCES

1. Koronowski, K. B. & Sassone-Corsi, P. Communicating clocks shape circadian homeostasis. Science 371, eabd0951 (2021).
2. Parilloaud, M. & Lamia, K. A. Cancer in the fourth dimension: what is the impact of circadian disruption? Cancer Discov. 10, 1455–1464 (2020).
3. Lee, Y. et al. G1/S cell cycle regulators mediate effects of circadian dysregulation on tumor growth and provide targets for timed anticancer treatment. PloS Biol. 17, e3000228 (2019).
4. Papapagkoupolous, T. et al. Circadian rhythm disruption promotes lung tumorigenesis. Cell Metab. 24, 324–331 (2016).
5. Hadad, E. et al. Chronic circadian disruption modulates breast cancer stemness and immune microenvironment to drive metastasis in mice. Nat. Commun. 11, 3193 (2020).
6. Aiello, I. et al. Circadian disruption promotes tumor-immune microenvironment remodeling favoring tumor cell proliferation. Sci. Adv. 6, eaaz4530 (2020).
7. Sulll, G., Lam, M. T. Y. & Panda, S. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer 5, 475–494 (2019).
8. Chak, A., Zarrinpar, A. & Panda, S. The circadian coordination of cell biology. J. Cell Biol. 215, 15–25 (2016).
9. Patke, A., Young, M. W. & Axelrod, S. Molecular mechanisms and physiological importance of circadian rhythms. Nat. Rev. Mol. Cell Biol. 21, 67–84 (2020).
10. Takahashi, J. S. Transcriptional architecture of the mammalian circadian clock. Nat. Rev. Genet. 18, 164–179 (2017).
11. Ancal, R. C. et al. Machine learning helps identify CHRONO as a circadian clock component. PloS Biol. 12, e1001840 (2014).
12. Lee, Y. et al. The NRON complex controls circadian clock function through regulated PER and CRY nuclear translocation. Sci. Rep. 9, 11883 (2019).
13. Brancaccio, M. et al. Cell-autonomous clock of astrocytes drives circadian behavior in mice. Science 363, 187–192 (2019).
14. Buijs, R. M., Guzman Ruiz, M. A., Mendez Hernandez, R. & Rodriguez Cortes, B. The suprachiasmatic nucleus; a responsive clock regulating homeostasis by daily changing the setpoints of physiological parameters. Auton. Neurosci. 218, 43–50 (2019).
15. Finger, A. M. & Kramer, A. Peripheral clocks tick independently of their master. Genes Dev. 35, 304–306 (2021).
16. Van Drunen, R. & Ekelk-Mahan, K. Circadian rhythms of the hypothalamus: from function to physiology. Clocks Sleep. 3, 169–226 (2021).
17. Gabriel, B. M. & Zerath, J. R. Circadian rhythms and exercise—resetting the clock in metabolic disease. Nat. Rev. Endocrinol. 15, 197–206 (2019).
18. Reinke, H. & Asher, G. Crotstalk between metabolism and circadian clocks. Nat. Rev. Mol. Cell Biol. 20, 227–241 (2019).
19. Scheiermann, C., Gibbs, J., Ince, L. & Loudon, A. Clocking in to immunity. Nat. Rev. Immunol. 18, 423–437 (2018).
20. Brum, M. C. B. et al. Night shift work, short sleep and obesity. Diabetol. Metab. Syndr. 12, 13 (2020).
21. IARC Monographs Vol 124 group. Circadianicity of night shift work. Lancet Oncol. 20, 1058–1059 (2019).
22. Filipski, E. & Lévi, F. Circadian disruption in experimental cancer processes. Integr. Cancer Ther. 8, 298–302 (2009).
23. Logan, R. W. et al. Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats. J. Immunol. 188, 2583–2591 (2012).
24. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
25. Taniguchi, H. et al. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res. 69, 8447–8454 (2009).
61. Alidadi, M. et al. The effect of caloric restriction and fasting on cancer. *Experimental & Molecular Medicine* (2021) 53:1529 – 1538

63. Zhao, X. et al. The role and its mechanism of intermittent fasting in tumors: A review of randomized controlled trials. *Compr. Physiol.* 16, 10310 (2017).

59. Lundell, L. S. et al. Time-restricted feeding alters lipid and amino acid metabolite homeostasis and treatment. *ASN Neuro.* 11, 175901419892713 (2019).

57. Kervezee, L., Cuesta, M., Cermakian, N. & Boivin, D. B. The Phase-Shifting Effect of Bright Light Exposure on Circadian Rhythmicity in the Human Transcriptome. *J. Biol. Rhythms* 34, 84–97 (2019).

55. Dauchy, R. T. et al. Effect of daytime blue-enriched LED light on the nighttime hormone melatonin in the treatment of advanced solid neoplasms. *Nat. Med.* 20, 409–410 (2014).

54. Dauchy, R. T. et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. *Cancer Res.* 74, 4099–4110 (2014).

65. Naja, Y. et al. Calorie restriction and fasting on cancer. *Science* 327, 63–73 (2010).

66. Naja, Y. et al. Dexamethasone resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal. *J. Pineal Res.* 59, 60–69 (2015).

53. Dauchy, R. T. et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. *Cancer Res.* 74, 4099–4110 (2014).

58. Kervezee, L., Cuesta, M., Cermakian, N. & Boivin, D. B. The Phase-Shifting Effect of Bright Light Exposure on Circadian Rhythmicity in the Human Transcriptome. *J. Biol. Rhythms* 34, 84–97 (2019).

53. Dauchy, R. T. et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. *Cancer Res.* 74, 4099–4110 (2014).

58. Kervezee, L., Cuesta, M., Cermakian, N. & Boivin, D. B. The Phase-Shifting Effect of Bright Light Exposure on Circadian Rhythmicity in the Human Transcriptome. *J. Biol. Rhythms* 34, 84–97 (2019).

53. Dauchy, R. T. et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. *Cancer Res.* 74, 4099–4110 (2014).
110. Dulong, S., Ballesta, A., Okyar, A. & Lévi, F. Identification of circadian determinants of cancer chronotherapy through in vitro chronopharmacology and mathematical modeling. Mol. Cancer Ther. 14, 2154–2164 (2015).

111. Slat, E. A. et al. Cell-intrinsic, Bmal1-dependent circadian regulation of temozolomide sensitivity in glioblastoma. J. Biol. Rhythms 32, 121–129 (2017).

112. Zeng, Z. L. et al. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clin. Cancer Res. 20, 1042–1052 (2014).

113. Tang, Q. et al. Periodic oxaliplatin administration in synergy with PER2-mediated PCNA transcription repression promotes chronotherapeutic efficacy of OSCC. Adv. Sci. 6, 1900667 (2019).

114. Matsunaga, N. et al. Optimized dosing schedule based on circadian dynamics of mouse breast cancer stem cells improves the antitumor effects of aldehyde dehydrogenase inhibitor. Cancer Res. 78, 3698–3708 (2018).

115. Sarma, A. et al. The circadian clock modulates anticancer properties of curcumin. BMC Cancer 16, 759 (2016).

116. Lee, Y. et al. Time-of-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle. Sci. Adv. 7, eabd2645 (2021).

117. Walker, W. H. 2nd et al. Light pollution and cancer. Int. J. Mol. Sci. 21, 9360 (2020).

118. Telias, I. & Wilcox, M. E. Sleep and circadian rhythm in critical illness. Crit. Care 23, 82 (2019).

ACKNOWLEDGEMENTS
This work was supported by the Elson S. Floyd College of Medicine to Y.L. We would like to thank Amy Sullivan, Ph.D. from Obrizus Communications for assisting with the helpful editing of this article.

COMPETING INTERESTS
The author declares no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Yool Lee.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021